Growth HormoneFDA Approved
Macimorelin
Also known as: AEZS-130 · Macrilen
An FDA-approved oral ghrelin receptor agonist used as a diagnostic tool for adult growth hormone deficiency.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~4–6 hours
Typical Dose
0.5 mg/kg single oral dose (diagnostic)
Administration
Oral
Mechanism of Action
Orally bioavailable ghrelin mimetic that triggers measurable GH spike within 60 minutes, enabling non-invasive GH deficiency diagnosis.
Key Research Areas
growth hormonediagnosticFDA approvedoral
Frequently Asked Questions
What is Macimorelin?▾
An FDA-approved oral ghrelin receptor agonist used as a diagnostic tool for adult growth hormone deficiency.
How does Macimorelin work?▾
Orally bioavailable ghrelin mimetic that triggers measurable GH spike within 60 minutes, enabling non-invasive GH deficiency diagnosis.
What is the recommended dosage for Macimorelin?▾
The typical research dosage is 0.5 mg/kg single oral dose (diagnostic), administered via Oral. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Macimorelin?▾
The half-life of Macimorelin is approximately ~4–6 hours. This affects dosing frequency and timing in research protocols.
Is Macimorelin FDA approved?▾
Yes, Macimorelin is FDA approved for specific medical indications. Consult your physician for proper medical guidance.
Research Disclaimer
The information provided about Macimorelin is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.